Psoriasis: Types, Symptoms, Causes and Complete Treatment Guide
- Dr. Tobias Kohler
- 6 days ago
- 9 min read
Psoriasis affects approximately 3% of American adults — over 8 million people — and carries an estimated economic burden of $112 billion annually in the United States in 2026, according to the latest psoriasis data reports. Yet it remains one of the most misunderstood skin conditions: many patients dismiss it as cosmetic, while others live with significant physical and psychological disability. Approximately 20,000 children under age 10 are newly diagnosed each year, underscoring that psoriasis is not exclusively an adult condition.
Psoriasis is a chronic, immune-mediated, systemic disease — not simply a skin condition. The immune dysfunction driving psoriatic skin plaques is the same process that causes psoriatic arthritis in approximately 30% of patients, and the same systemic inflammation that increases the risk of cardiovascular disease, metabolic syndrome, and depression. Treating psoriasis comprehensively means addressing the whole patient, not just the skin.
In 2026, the treatment landscape for psoriasis has never been stronger — biologics targeting specific cytokines now produce near-complete skin clearance in the majority of patients with moderate-to-severe disease, and newer oral agents offer effective options without injection.
This complete guide covers all psoriasis types, how to recognise it, what triggers it, what drives it biologically, and the complete 2026 treatment pathway from topical creams to advanced biologics.
The American Academy of Dermatology provides a comprehensive psoriasis overview at: https://www.aad.org/public/diseases/psoriasis/what/overview
What is Psoriasis? — The Immune-Mediated Mechanism
Psoriasis is an immune-mediated condition in which the immune system — specifically overactivated T cells and dendritic cells — triggers an inflammatory cascade that dramatically accelerates the skin cell lifecycle.
In normal skin, new skin cells form in the deeper layers and take approximately 28–30 days to rise to the surface and shed naturally. In psoriasis, this process is compressed to just 3–5 days. The result: vast numbers of immature skin cells pile up on the surface before they can mature and shed, forming the characteristic thick, scaly plaques.
The inflammatory cytokines primarily responsible are TNF-alpha, IL-17, IL-23, and IL-12 — which is why modern biologic treatments target these specific molecules with extraordinary precision and effectiveness.
Psoriasis is NOT contagious. It cannot be spread through any form of contact. This remains one of the most important misconceptions to correct.
The 5 Types of Psoriasis
Plaque psoriasis (most common — 80–90% of all cases):
Raised, red or discoloured plaques covered with a silvery-white scale, typically appearing on the scalp, elbows, knees, lower back, and nails. Plaques can range from a few small patches to covering large areas of the body. The defining characteristic is the thick, adherent scale. May itch, burn, or be painless. Severity is classified by body surface area (BSA) and PASI (Psoriasis Area and Severity Index) score.
Guttate psoriasis:
Small, teardrop-shaped red spots scattered across the trunk, arms, and legs — often appearing suddenly following a streptococcal throat infection. Most common in children and young adults. May resolve spontaneously or evolve into plaque psoriasis in some patients.
Inverse psoriasis:
Affects skin folds — armpits, groin, under breasts, and around the genitals. Presents as smooth, red, shiny patches without the typical scale (moisture prevents scale formation in skin folds). Often mistaken for fungal infection. Particularly sensitive to friction and sweating.
Pustular psoriasis:
Characterised by white, pus-filled blisters (pustules) surrounded by red skin. Pustules contain white blood cells — not bacterial infection. Can be localised (palmoplantar pustulosis — affecting palms and soles) or generalised (Von Zumbusch type — a medical emergency with widespread pustules, fever, and systemic illness).
Erythrodermic psoriasis:
The rarest and most severe form — widespread redness and scaling covering most of the body surface. A medical emergency: can cause severe protein loss, fluid imbalance, infection, and cardiovascular instability. Requires hospitalisation.
Symptoms and Features of Psoriasis
Skin symptoms (common to most types):
Red, raised, inflamed patches (plaques) — vary in shade by skin tone; may appear pink/red on lighter skin and purple, brown, or greyish on darker skin
Thick, silvery-white or greyish scales on plaques
Dry skin that may crack and bleed
Itching, burning, or soreness — severity varies widely; some patients have severe itch, others none
Thickened, pitted, or ridged nails (nail psoriasis) — affects up to 50% of psoriasis patients; nail changes can precede psoriatic arthritis
Psoriatic arthritis (in approximately 30% of patients):
Joint inflammation occurring in conjunction with psoriasis. May affect any joint but most commonly the fingers and toes (often causing characteristic "sausage digits" — dactylitis), lower back (sacroiliitis), and larger joints. Psoriatic arthritis can cause permanent joint damage if untreated. Skin and joint disease do not necessarily correlate in severity — mild skin disease can coexist with severe joint involvement. Key distinguishing features from rheumatoid arthritis: typically asymmetric, involves DIP joints, associated with nail changes, seronegative (negative rheumatoid factor in most cases).
Systemic and psychological impact:
Cardiovascular risk
systemic TNF-alpha and IL-17 driven inflammation accelerates atherosclerosis; severe psoriasis carries similar cardiovascular risk to diabetes and hypertension as independent risk factors
Metabolic syndrome
obesity, insulin resistance, and dyslipidaemia are all more common in psoriasis
Depression and anxiety
20.3% of US psoriasis patients have comorbid depression; the visible and stigmatising nature of the condition significantly impacts mental health
Inflammatory bowel disease
Crohn's disease specifically shares immune pathways with psoriasis (TNF-alpha, IL-23)
What Causes and Triggers Psoriasis?
Psoriasis arises from a combination of genetic susceptibility and environmental triggers:
Genetic factors:
Psoriasis has a strong genetic component — approximately 10% of the general population inherits genes associated with psoriasis, but only 2–3% develop the condition, meaning environmental triggers are required. The strongest genetic association is with HLA-Cw6 — present in approximately 60% of psoriasis patients. Having a first-degree relative with psoriasis roughly doubles lifetime risk.
Immune dysregulation:
The central mechanism involves overactivation of Th17 cells producing IL-17, and activation of the IL-23/Th17 axis — which is why IL-17 and IL-23 inhibitor biologics produce such dramatic efficacy in psoriasis.
Common triggers (can initiate or worsen psoriasis):
Stress
psychological stress is the most commonly reported trigger; activates the HPA axis and inflammatory cytokines
Infections
streptococcal throat infections classically trigger guttate psoriasis; any systemic infection can worsen disease
Skin injury
the Koebner phenomenon: new psoriatic plaques developing at sites of skin trauma (cuts, sunburn, surgical scars)
Medications
lithium, beta-blockers, antimalarials, NSAIDs, and ACE inhibitors can all trigger or worsen psoriasis
Alcohol
heavy use is a significant trigger and worsens treatment response
Smoking
strongly associated with pustular psoriasis specifically and with disease severity generally
Obesity
excess adipose tissue produces pro-inflammatory cytokines (TNF-alpha, IL-6) that drive psoriasis; weight loss significantly improves skin disease
Hormonal changes
puberty, pregnancy, and menopause can all affect psoriasis activity
Treatment of Psoriasis — The 2026 Stepped Approach
Treatment is based on disease severity (mild, moderate, or severe) assessed by BSA and PASI score, and by impact on quality of life:
Mild psoriasis (less than 3% BSA — most patients):
Topical therapies are the cornerstone:
Topical corticosteroids
most widely used; reduce inflammation, scaling, and itch rapidly; available in multiple potencies from mild (hydrocortisone) to very potent (clobetasol); used intermittently to avoid skin thinning with prolonged use
Vitamin D analogues (calcipotriol/calcitriol)
slow skin cell production; highly effective combined with topical steroids; available as combination products (Dovobet, Enstilar foam)
Coal tar
anti-inflammatory and antiproliferative; available OTC; useful for scalp and chronic plaques
Tapinarof cream (Vtama)
FDA-approved 2022; novel non-steroidal topical; aryl hydrocarbon receptor agonist; does not cause skin thinning
Roflumilast cream (Zoryve)
FDA-approved 2022; non-steroidal PDE4 inhibitor; excellent for sensitive areas including face and intertriginous zones
Phototherapy (moderate psoriasis or widespread mild):
Narrowband UVB (NB-UVB)
the most commonly used phototherapy; 2–3 sessions weekly; highly effective for plaque and guttate psoriasis; safe in pregnancy
PUVA (psoralen + UVA)
more potent; used for thick plaques and palmoplantar psoriasis; not used in pregnancy
Systemic non-biologic therapies (moderate-to-severe):
Methotrexate
the classic systemic agent; oral weekly dose; effective for both skin and psoriatic arthritis; requires regular liver function monitoring; teratogenic — avoid in pregnancy
Cyclosporin
fast-acting; used for severe flares or as a bridge to biologic; short-term use only due to nephrotoxicity and hypertension
Acitretin
oral retinoid; particularly effective for pustular and erythrodermic psoriasis; teratogenic with prolonged post-treatment contraception requirement
Apremilast (Otezla)
oral PDE4 inhibitor; FDA-approved for moderate-to-severe plaque psoriasis; modest but reliable efficacy; good tolerability; no laboratory monitoring required
Deucravacitinib (Sotyktu)
oral TYK2 inhibitor; FDA-approved 2022; superior to apremilast and placebo; no required laboratory monitoring; increasingly used in 2026
Biologic therapies (moderate-to-severe — the current gold standard):
Biologics targeting specific inflammatory cytokines produce the most dramatic skin clearance — PASI 90 (90% improvement in skin score) or greater in the majority of patients in clinical trials:
TNF-alpha inhibitors (older generation):
Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade) — effective for both skin and psoriatic arthritis; now largely superseded for skin disease but still used for joint disease
IL-17 inhibitors (highly effective for skin):
Secukinumab (Cosentyx)
targets IL-17A; produces PASI 90 in approximately 70–80% of patients
Ixekizumab (Taltz)
targets IL-17A; similar efficacy to secukinumab
Bimekizumab (Bimzelx)
targets both IL-17A and IL-17F; FDA-approved 2023; highest skin clearance rates of any biologic — PASI 100 (complete clearance) in approximately 60–70% of patients
IL-23 inhibitors (highly effective, less frequent dosing):
Guselkumab (Tremfya)
IL-23 specific (p19 subunit); injected every 8 weeks after loading
Risankizumab (Skyrizi)
IL-23 specific; quarterly dosing after loading; exceptional efficacy including PASI 100 rates
Tildrakizumab (Ilumya)
IL-23 specific; every 12-week maintenance
IL-12/23 inhibitor:
Ustekinumab (Stelara) — targets both IL-12 and IL-23; every 12-week maintenance; also effective for Crohn's disease
Treatment Comparison Table
Treatment | Type | Severity | PASI 75 Rate | Key Advantage |
Topical steroids | Topical | Mild | Variable | Fast, accessible, cheap |
Calcipotriol combo | Topical | Mild-moderate | ~50% | No skin thinning risk |
Tapinarof (Vtama) | Topical (novel) | Mild-moderate | ~35–40% | No skin thinning; new mechanism |
NB-UVB phototherapy | Phototherapy | Mild-moderate | ~60–70% | Safe in pregnancy |
Methotrexate | Systemic | Moderate-severe | ~40–50% | Cheap; treats joints |
Apremilast (Otezla) | Oral biologic-sparing | Moderate | ~33% | No monitoring; oral |
Deucravacitinib (Sotyktu) | Oral TYK2 | Moderate-severe | ~53% | Superior to apremilast; oral |
Adalimumab (Humira) | TNF biologic | Moderate-severe | ~60–70% | Also treats joints; biosimilars available |
Secukinumab (Cosentyx) | IL-17 biologic | Moderate-severe | ~70–80% | Fast onset; skin + joints |
Bimekizumab (Bimzelx) | IL-17A+F biologic | Moderate-severe | ~85–90% | Highest PASI 90/100 rates |
Risankizumab (Skyrizi) | IL-23 biologic | Moderate-severe | ~75–80% | Quarterly dosing; high PASI 100 |
Psoriasis and the Medications That Can Worsen It
Medication | Effect on Psoriasis | What to Do |
Lithium | Triggers and worsens psoriasis significantly | Discuss alternatives with psychiatrist |
Beta-blockers | Can trigger or worsen — especially propranolol | Switch to calcium channel blocker if possible |
Antimalarials (hydroxychloroquine) | May trigger flares — use cautiously | Discuss risk vs benefit with rheumatologist |
NSAIDs (ibuprofen, naproxen) | Can worsen in some patients | Use paracetamol where possible |
ACE inhibitors | Reported to trigger in some patients | Switch to ARB if suspected |
Alcohol | Worsens severity and impairs treatment response | Reduce or eliminate |
Abrupt steroid withdrawal | Can trigger severe rebound flare | Taper systemic steroids slowly |
For our complete guide on Hydroxychloroquine (HCQS) — used in autoimmune conditions but requiring caution in psoriasis: [Hydroxychloroquine (HCQS) for Lupus and Rheumatoid Arthritis]
For our guide on depression — affecting over 20% of psoriasis patients in the US: [Depression: Symptoms, Causes and Treatment]
For our complete guide on hair loss — scalp psoriasis is a common and frequently missed cause: [What Causes Hair Loss? Types, Causes and Treatments]
Full AAD psoriasis treatment guidance and 2026 updates are available at: https://www.aad.org/public/diseases/psoriasis/treatment/treatment
The National Psoriasis Foundation provides statistics and patient resources at: https://www.psoriasis.org/psoriasis-statistics/
Frequently Asked Questions
Is psoriasis contagious?
No — psoriasis is not contagious in any way. It cannot be spread through skin contact, sharing towels, touching, kissing, or any other form of contact. Psoriasis is an immune-mediated condition driven by the person's own immune system attacking their skin. This is one of the most important misconceptions about psoriasis and one that causes significant unnecessary social stigma and isolation for patients.
Can psoriasis go away permanently?
Psoriasis is a chronic condition — it cannot currently be cured. However, it is episodic for many patients: periods of flare alternate with periods of remission in which skin may clear partially or completely. With modern biologic therapies, many patients achieve complete or near-complete skin clearance that can be maintained long-term. Some patients — particularly those with guttate psoriasis following a single infection — may experience very prolonged natural remission. Triggers such as stress, smoking, and obesity should be addressed to reduce flare frequency.
What is psoriatic arthritis and how do I know if I have it?
Psoriatic arthritis (PsA) is joint inflammation occurring in approximately 30% of psoriasis patients. It typically causes pain, swelling, and stiffness in the fingers, toes, lower back, or larger joints. Warning signs include morning joint stiffness lasting more than 30 minutes, sausage-like swelling of entire fingers or toes (dactylitis), lower back pain that improves with movement, and nail pitting or changes. PsA can cause permanent joint damage if untreated — early diagnosis and treatment with a rheumatologist is critical. All patients with psoriasis should be screened regularly for PsA.
Are biologics for psoriasis safe?
Current biologics for psoriasis — particularly IL-17 and IL-23 inhibitors — have an excellent long-term safety profile established over 10 or more years of use in clinical practice. They are associated with a slightly increased risk of certain infections (particularly upper respiratory infections) and require screening for tuberculosis before starting. They are generally avoided in active serious infections, certain cancers, and some demyelinating conditions. IL-17 inhibitors may exacerbate inflammatory bowel disease. Each biologic has a specific safety profile that a dermatologist will discuss individually.
Does diet affect psoriasis?
Yes — diet and lifestyle have meaningful effects on psoriasis severity. Obesity significantly worsens psoriasis by increasing systemic inflammation; weight loss in obese patients consistently improves PASI scores and improves biologic response. Alcohol consumption worsens psoriasis severity and impairs treatment response — patients on methotrexate must not drink alcohol. The Mediterranean diet has the strongest evidence base for reducing systemic inflammation and is associated with lower psoriasis severity in observational studies. Gluten-free diets benefit only patients with confirmed coeliac disease or documented anti-gliadin antibodies.
Comments